21 Cfr 809 (2024)

1. CFR - Code of Federal Regulations Title 21 - FDA

  • § 809.20 - General requirements for manufacturers and producers of in vitro diagnostic products. § 809.30 - Restrictions on the sale, distribution and use of ...

  • -

2. 21 CFR Part 809 -- In Vitro Diagnostic Products for Human Use - eCFR

  • General requirements for manufacturers and producers of in vitro diagnostic products. § 809.30, Restrictions on the sale, distribution and use of analyte ...

  • (a) The label for an in vitro diagnostic product shall state the following information, except where such information is not applicable, or as otherwise specified in a standard for a particular product class or as provided in paragraph (e) of this section. Section 201(k) of the act provides that “a requirement made by or under authority of this act that any word, statement, or other information appear on the label shall not be considered to be complied with unless such word, statement, or other information also appears on the outside container or wrapper, if any there be, of the retail package of such article, or is easily legible through the outside container or wrapper.”

3. 21 CFR Part 809 | US Law | LII / Legal Information Institute

4. [PDF] Food and Drug Administration 21 CFR Part 809 [Docket No. FDA-2023-N ...

  • Sep 29, 2023 · We anticipate that applying the same oversight approach to laboratories and non-laboratories that manufacture IVDs would better assure the ...

5. 21 CFR 809 - In-Vitro Diagnostic Products - GMP Publications

6. 21 CFR 809 In Vitro Diagnostic Products for Human Use with TOC

  • Introduction to Process Validation; Documentation & Audit Preparation; Mechanical Blueprint Reading; Welding Blueprint Reading; FDA Inspection ...

  • Awards & Memberships

7. [PDF] Draft Guidance for Industry and FDA Staff In Vitro Diagnostic (IVD ...

  • Oct 25, 2007 · 21 CFR Part 809, In Vitro Diagnostic Products for Human Use, found at http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfCFR/CFRSearch.cfm ...

8. FDA's Final Rule on Laboratory-Developed Tests

  • May 8, 2024 · at 37444-45 (amending 21 C.F.R. § 809.3(a)). [4] As amended, the authorities for Part 809 now list the following: “21 U.S.C. 321(h)(1), 331 ...

  • The U.S. Food and Drug Administration's highly anticipated final rule on laboratory-developed tests was officially published in the Federal Register on Monday, May 6, 2024.

9. 0910-AI85 - View Rule

  • CFR Citation: 21 CFR 809. Legal Authority: 21 U.S.C. 321 21 U.S.C. 331 21 U.S.C. 351 21 U.S.C. 352 21 U.S.C. 360c ... Legal Deadline: None. Timetable: Action ...

  • This proposed rule would propose to amend the Food and Drug Administration’s regulations to make explicit that laboratory developed tests (LDTs) are devices under the Federal Food, Drug, and Cosmetic Act.

10. Am I Complying with FDA Medical Device Labeling Requirements?

  • Apr 4, 2021 · 21 CFR Part 809 covers in vitro diagnostic products. Subpart B of the FDA regulation covers the labeling of those devices. This is quite an ...

  • How to understand and follow medical device labeling requirements from FDA for ongoing compliance.

21 Cfr 809 (2024)

References

Top Articles
Latest Posts
Article information

Author: Barbera Armstrong

Last Updated:

Views: 5853

Rating: 4.9 / 5 (79 voted)

Reviews: 86% of readers found this page helpful

Author information

Name: Barbera Armstrong

Birthday: 1992-09-12

Address: Suite 993 99852 Daugherty Causeway, Ritchiehaven, VT 49630

Phone: +5026838435397

Job: National Engineer

Hobby: Listening to music, Board games, Photography, Ice skating, LARPing, Kite flying, Rugby

Introduction: My name is Barbera Armstrong, I am a lovely, delightful, cooperative, funny, enchanting, vivacious, tender person who loves writing and wants to share my knowledge and understanding with you.